ParkinsonCanadaV1, Main, Exploration, bibRecord, 002649

Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease

Identifieur interne : 002649 ( Main/Exploration ); précédent : 002648; suivant : 002650

Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease

Auteurs : R. L. Watts [États-Unis] ; Joseph Jankovic [États-Unis] ; C. Waters [États-Unis] ; A. Rajput [Canada] ; B. Boroojerdi [Allemagne] ; J. Rao [États-Unis]

Source :

Neurology [ 0028-3878 ] ; 2007.

RBID : Pascal:07-0109049

Descripteurs français

Pascal (Inist)
- Système nerveux pathologie, Parkinson maladie, Rotigotine.

English descriptors

KwdEn :
- Nervous system diseases, Parkinson disease, Rotigotine.

Abstract

Objective: This multicenter, randomized, double-blind study was performed to compare the safety and efficacy of the once-daily dopamine agonist rotigotine, in a continuous-dosing transdermal-patch formulation, vs placebo in patients with early-stage Parkinson disease (PD). Methods: Patients were randomized to receive placebo (n = 96) or rotigotine (n = 181), starting at 2 mg/24 h (10-cm² patch size; 4.5-mg total drug content), titrated weekly up to 6 mg/24 h (30-cm² patch size; 13.5-mg total drug content), and then maintained for 6 months. The primary efficacy measures were 1) the change in the Unified Parkinson's Disease Rating Scale (UPDRS) scores (parts II and III) from baseline to end of treatment and 2) responder rates (patients with ≥20% improvement). Results: Patients receiving rotigotine had a mean absolute difference of 5.28 (±1.18) points lower in UPDRS subtotal scores compared with those receiving placebo (p < 0.0001). The mean change in part III motor scores was -3.50 (±7.26) (n = 177) and was the greatest contributor to UPDRS improvement. The rotigotine group had more responders (48 vs 19%; p < 0.0001). The most commonly reported adverse events were application site reactions (44% rotigotine vs 12% placebo), nausea (41 vs17%), somnolence (33 vs 20%), and dizziness (19 vs 13%), and most were mild or moderate in intensity. Conclusions: Transdermal rotigotine, when titrated to a dosage of 6 mg/24 h, was effective for the treatment of early-stage Parkinson disease in this trial. Adverse events were similar to those found with other transdermal systems and dopamine agonists.

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 000771
to stream PascalFrancis, to step Curation: 000549
to stream PascalFrancis, to step Checkpoint: 000609
to stream Main, to step Merge: 002899
to stream Main, to step Curation: 002649

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease</title>
<author><name sortKey="Watts, R L" sort="Watts, R L" uniqKey="Watts R" first="R. L." last="Watts">R. L. Watts</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>University of Alabama at Birmingham</s1>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>University of Alabama at Birmingham</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J." last="Jankovic">Joseph Jankovic</name>
<affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Baylor College of Medicine</s1>
<s2>Houston, TX</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">Houston</settlement>
<region type="state">Texas</region>
</placeName>
<orgName type="university">Baylor College of Medicine</orgName>
<placeName><settlement type="city">Houston</settlement>
<region type="state">Texas</region>
</placeName>
<orgName type="university" n="3">Baylor College of Medicine</orgName>
</affiliation>
</author>
<author><name sortKey="Waters, C" sort="Waters, C" uniqKey="Waters C" first="C." last="Waters">C. Waters</name>
<affiliation wicri:level="4"><inist:fA14 i1="03"><s1>Columbia University</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">New York</settlement>
<region type="state">État de New York</region>
</placeName>
<orgName type="university">Université Columbia</orgName>
</affiliation>
</author>
<author><name sortKey="Rajput, A" sort="Rajput, A" uniqKey="Rajput A" first="A." last="Rajput">A. Rajput</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>University of Saskatchewan</s1>
<s2>Saskatoon</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>University of Saskatchewan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Boroojerdi, B" sort="Boroojerdi, B" uniqKey="Boroojerdi B" first="B." last="Boroojerdi">B. Boroojerdi</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Schwarz Pharma</s1>
<s2>Monheim</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Monheim</wicri:noRegion>
<wicri:noRegion>Schwarz Pharma</wicri:noRegion>
<wicri:noRegion>Schwarz Pharma</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rao, J" sort="Rao, J" uniqKey="Rao J" first="J." last="Rao">J. Rao</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Louisiana State University</s1>
<s2>Baton Rouge</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Louisiana State University</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">07-0109049</idno>
<date when="2007">2007</date>
<idno type="stanalyst">PASCAL 07-0109049 INIST</idno>
<idno type="RBID">Pascal:07-0109049</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000771</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000549</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000609</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000609</idno>
<idno type="wicri:doubleKey">0028-3878:2007:Watts R:randomized:blind:controlled</idno>
<idno type="wicri:Area/Main/Merge">002899</idno>
<idno type="wicri:Area/Main/Curation">002649</idno>
<idno type="wicri:Area/Main/Exploration">002649</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease</title>
<author><name sortKey="Watts, R L" sort="Watts, R L" uniqKey="Watts R" first="R. L." last="Watts">R. L. Watts</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>University of Alabama at Birmingham</s1>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>University of Alabama at Birmingham</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J." last="Jankovic">Joseph Jankovic</name>
<affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Baylor College of Medicine</s1>
<s2>Houston, TX</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">Houston</settlement>
<region type="state">Texas</region>
</placeName>
<orgName type="university">Baylor College of Medicine</orgName>
<placeName><settlement type="city">Houston</settlement>
<region type="state">Texas</region>
</placeName>
<orgName type="university" n="3">Baylor College of Medicine</orgName>
</affiliation>
</author>
<author><name sortKey="Waters, C" sort="Waters, C" uniqKey="Waters C" first="C." last="Waters">C. Waters</name>
<affiliation wicri:level="4"><inist:fA14 i1="03"><s1>Columbia University</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">New York</settlement>
<region type="state">État de New York</region>
</placeName>
<orgName type="university">Université Columbia</orgName>
</affiliation>
</author>
<author><name sortKey="Rajput, A" sort="Rajput, A" uniqKey="Rajput A" first="A." last="Rajput">A. Rajput</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>University of Saskatchewan</s1>
<s2>Saskatoon</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>University of Saskatchewan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Boroojerdi, B" sort="Boroojerdi, B" uniqKey="Boroojerdi B" first="B." last="Boroojerdi">B. Boroojerdi</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Schwarz Pharma</s1>
<s2>Monheim</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Monheim</wicri:noRegion>
<wicri:noRegion>Schwarz Pharma</wicri:noRegion>
<wicri:noRegion>Schwarz Pharma</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rao, J" sort="Rao, J" uniqKey="Rao J" first="J." last="Rao">J. Rao</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Louisiana State University</s1>
<s2>Baton Rouge</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Louisiana State University</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Neurology</title>
<title level="j" type="abbreviated">Neurology</title>
<idno type="ISSN">0028-3878</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Neurology</title>
<title level="j" type="abbreviated">Neurology</title>
<idno type="ISSN">0028-3878</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Rotigotine</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Parkinson maladie</term>
<term>Rotigotine</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Objective: This multicenter, randomized, double-blind study was performed to compare the safety and efficacy of the once-daily dopamine agonist rotigotine, in a continuous-dosing transdermal-patch formulation, vs placebo in patients with early-stage Parkinson disease (PD). Methods: Patients were randomized to receive placebo (n = 96) or rotigotine (n = 181), starting at 2 mg/24 h (10-cm<sup>2</sup>
 patch size; 4.5-mg total drug content), titrated weekly up to 6 mg/24 h (30-cm<sup>2</sup>
 patch size; 13.5-mg total drug content), and then maintained for 6 months. The primary efficacy measures were 1) the change in the Unified Parkinson's Disease Rating Scale (UPDRS) scores (parts II and III) from baseline to end of treatment and 2) responder rates (patients with ≥20% improvement). Results: Patients receiving rotigotine had a mean absolute difference of 5.28 (±1.18) points lower in UPDRS subtotal scores compared with those receiving placebo (p < 0.0001). The mean change in part III motor scores was -3.50 (±7.26) (n = 177) and was the greatest contributor to UPDRS improvement. The rotigotine group had more responders (48 vs 19%; p < 0.0001). The most commonly reported adverse events were application site reactions (44% rotigotine vs 12% placebo), nausea (41 vs17%), somnolence (33 vs 20%), and dizziness (19 vs 13%), and most were mild or moderate in intensity. Conclusions: Transdermal rotigotine, when titrated to a dosage of 6 mg/24 h, was effective for the treatment of early-stage Parkinson disease in this trial. Adverse events were similar to those found with other transdermal systems and dopamine agonists.</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>Canada</li>
<li>États-Unis</li>
</country>
<region><li>Texas</li>
<li>État de New York</li>
</region>
<settlement><li>Houston</li>
<li>New York</li>
</settlement>
<orgName><li>Baylor College of Medicine</li>
<li>Université Columbia</li>
</orgName>
</list>
<tree><country name="États-Unis"><noRegion><name sortKey="Watts, R L" sort="Watts, R L" uniqKey="Watts R" first="R. L." last="Watts">R. L. Watts</name>
</noRegion>
<name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J." last="Jankovic">Joseph Jankovic</name>
<name sortKey="Rao, J" sort="Rao, J" uniqKey="Rao J" first="J." last="Rao">J. Rao</name>
<name sortKey="Waters, C" sort="Waters, C" uniqKey="Waters C" first="C." last="Waters">C. Waters</name>
</country>
<country name="Canada"><noRegion><name sortKey="Rajput, A" sort="Rajput, A" uniqKey="Rajput A" first="A." last="Rajput">A. Rajput</name>
</noRegion>
</country>
<country name="Allemagne"><noRegion><name sortKey="Boroojerdi, B" sort="Boroojerdi, B" uniqKey="Boroojerdi B" first="B." last="Boroojerdi">B. Boroojerdi</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002649 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002649 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:07-0109049
   |texte=   Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease

Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri